Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
The European Union is currently negotiating new rules on European trademarks and are proposing language which will increase the risk of generic lifesaving medicines being stopped, seized and even destroyed while they are in transit in Europe en route to people in developing countries.
Last updated 3 December 2014
A letter to India's newly constituted IPR Think Tank, authored by MSF and signed by patient groups, public interest organisations, treatment providers and academia world-wide, raises critical issues around the intellectual property system in India. A particular area of concern is pharmaceuticals, as India is a key global supplier of affordable generic versions of drugs that otherwise would be out of reach for public health programmes, treatment providers and millions of people.
Last updated 1 December 2014
18 November 2014 The Tufts Center for the Study of Drug Development has just released its latest study on the average cost of developing a new drug. The average figure, released by Tufts CSDD, is US$2.588 billion ($2.56 billion).
Last updated 18 November 2014
Background Pharmaceutical company Bristol-Myers Squibb (BMS) has recently revealed a restrictive commercial strategy for sales of its new direct-acting antiviral (DAA) hepatitis C drug daclatasvir in developing countries. This new generation of drugs to treat hepatitis C is giving hope to the 185 million people infected with the disease today, as these drugs are expected to improve treatment and provide significantly higher chances of cure.
Last updated 3 November 2014
Last updated 22 October 2014
October 20th, 2014 To: President Jacob Zuma Minister of Trade and Industry Rob Davies Re: Promoting Access to Affordable Medicines in South Africa through Patent Law Reform
Last updated 20 October 2014
In recent days, the U.S. government has further stepped up its longstanding attacks (timeline: http://bit.ly/1qzMxd3) on India’s intellectual property regime – attacks conducted on behalf of the U.S. pharmaceutical industry, which sees generic competition from India as undermining its business interests.
Last updated 17 October 2014
Comments from GSK have emerged today suggesting that an Ebola vaccine will be 'too late' to have an impact on the current Ebola outbreak. Médecins Sans Frontières (MSF), which is at the forefront of responding to the epidemic in West Africa, is dismayed by these comments, given the unpredictability of the outbreak and the uncertainty over how long it could last. A vaccine could be the tipping point in this outbreak, and urgent development, in parallel with scaling up supply, could prove significant in saving lives, both in this outbreak and in future ones.
Last updated 17 October 2014
16 October, 2014 Today Wikileaks published a revised copy of the intellectual property chapter from the secret Trans-Pacific Partnership (TPP) negotiations: https://wikileaks.org/tpp-ip2/. The leaked document -- dated May 2014 – also discloses countries’ current negotiating positions. Wikileaks had released an earlier version of the IP chapter in November 2013.
Last updated 16 October 2014
Interview on experimental treatments and vaccines with Dr Bertrand Draguez, MSF Medical Director
Last updated 15 October 2014